
EMA Recommends Restrictions on Multiple Sclerosis Medicine
The agency’s Pharmacovigilance Risk Assessment Committee made recommendations on the risk of multiple sclerosis treatments, injectable methylprednisolone medicines, and the use of gadolinium contrast agents.
The European Medicines Agency (EMA)
PRAC recommended that injectable methylprednisolone medicines containing lactose must not be used by patients with an allergy to the proteins in cow’s milk. The committee also recommended that cow’s milk proteins be removed from the preparation of injectable methylprednisolone. Injectable methylprednisolone is used to treat the symptoms of severe allergic reaction.
At the meeting, PRAC confirmed its restrictions on the use of linear gadolinium agents.
The committee previously determined that there is evidence of gadolinium deposition in brain tissues following use of gadolinium contrast agents.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.